Skip to content
18 November · 06:30 UTCFollow AstraZeneca by emailFollow

AZN · Pharma and healthcare · one day

AstraZeneca (AZN): news on Tuesday 17 November 2026

News from the 24 hours to Tuesday morning, 17 November 2026.

Tone of the day

+9.7strongly positive
Relevant headlines45of 49 read
Stories13grouped by event

What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.

Why it scored this way

Coverage was led by a string of regulatory successes, chiefly US and EU clearance for Klygefa, the myasthenia gravis treatment, US clearance for Imfinzi in bladder cancer and a European recommendation for the blood pressure drug Baxfendy. Smaller counterweights were reported US job cuts, a regulator's rejection of a partner's cancer drug and a busy myasthenia market.

What drove it

  • Klygefa approvals
  • Imfinzi bladder cancer approval
  • Baxfendy EU recommendation

Around this day

DayToneHeadlines
Wed 11 Nov+6.322
Thu 12 Nov+7.525
Fri 13 Nov+5.38
Sat 14 Nov+5.539
Sun 15 Nov+7.59
Mon 16 Nov+4.56
Tue 17 Nov+9.745
Wed 18 Nov+7.029

13 stories · 45 headlines · strongest first

Pharma and healthcare on 17 NovemberFTSE 100 that day
ToneWhat the article reported, and why it scored that waySource
AstraZeneca's Klygefa approved for myasthenia gravis in US and EU +10.016 headlines today · 19 in all, since 15 November · Outlets report Klygefa has won EU approval alongside its US approval for generalised myasthenia gravis.
+10.0Two US regulatory clearances for new uses and a new drug.PharmTech.com (opens the article) ↗
+10.0New drug cleared in both US and Europe.Zacks Investment Research (opens the article) ↗
+10.0Next-generation therapy cleared in both markets.FirstWord Pharma (opens the article) ↗
+10.0American regulator clears new generalised myasthenia treatment.BioPharm International (opens the article) ↗
+10.0Rare muscle disorder drug cleared in two regions.Sharecast (opens the article) ↗
+10.0Self-administered therapy cleared in US and Europe.AllSci (opens the article) ↗
+10.0European clearance for myasthenia treatment.Quantisnow (opens the article) ↗
+10.0Approvals secured on both sides of Atlantic.Yahoo Finance UK (opens the article) ↗
+10.0European clearance for myasthenia drug.Securities.io (opens the article) ↗
+10.0US clearance for myasthenia treatment.Quantisnow (opens the article) ↗
+10.0Adult myasthenia drug cleared in Europe.MarketScreener (opens the article) ↗
+10.0European clearance for myasthenia treatment.StreetInsider (opens the article) ↗
+10.0Transatlantic approvals for new drug lift outlook.AD HOC NEWS (opens the article) ↗
+10.0US and European clearance for autoimmune treatment.London South East (opens the article) ↗
+8.3Part of roundup noting approvals for its myasthenia asset.Sharecast (opens the article) ↗
+5.0Approval positive, but competition in the field is heavy.Endpoints News (opens the article) ↗
FDA approves Imfinzi regimen for bladder cancer +10.06 headlines today · 15 in all, since 14 November · Coverage reports US approval of Imfinzi with chemotherapy for cisplatin-ineligible muscle-invasive bladder cancer.
+10.0US clearance for broader use of cancer drug and new therapy.Reuters (opens the article) ↗
+10.0US clearance for bladder cancer combination.AllSci (opens the article) ↗
+10.0US clearance for bladder cancer combination.Pharmaceutical Technology (opens the article) ↗
+10.0Company announcement of US bladder cancer clearance.TradingView (opens the article) ↗
+10.0Two drugs cleared in US.Investing.com (opens the article) ↗
+10.0US clearance for bladder cancer regimen.TipRanks (opens the article) ↗
EU committee recommends AstraZeneca's Baxfendy for hypertension +8.66 headlines today · 14 in all, since 14 November · Reports cover the EU panel's recommendation of Baxfendy for uncontrolled hypertension.
+8.3Positive European recommendation backed by late-stage trials.Yahoo Finance UK (opens the article) ↗
+8.3European committee backing following US clearance.AllSci (opens the article) ↗
+8.3Blood pressure drug backed for European clearance.lifesciencefocus.com (opens the article) ↗
+8.3European committee supports hypertension drug.Quantisnow (opens the article) ↗
+8.3European panel backs blood pressure medicine.Stock Titan (opens the article) ↗
+8.3European support for hypertension drug.AD HOC NEWS (opens the article) ↗
AstraZeneca wins several regulatory approvals +9.35 headlines today · 8 in all · Round-ups cover several AstraZeneca approvals spanning rare disease, bladder cancer and blood pressure.
+10.0Four regulatory successes across several areas.Proactive Investors UK (opens the article) ↗
+10.0Several approvals covering bladder cancer and a rare disease.Benzinga (opens the article) ↗
+9.2Briefing highlights its regulatory successes.London South East (opens the article) ↗
+9.2Progress across three treatment areas.DirectorsTalk Interviews (opens the article) ↗
+6.7General positive coverage of new medicines progress.Kalkine Media (opens the article) ↗
AstraZeneca unit defeats Soliris monopolisation suit +8.32 headlines today · 4 in all · A lawsuit by an insurer alleging Soliris monopolisation was defeated.
+8.3Company avoids litigation over alleged market dominance of a drug.Reuters (opens the article) ↗
+8.3Subsidiary wins dismissal of insurer's competition claim.Bloomberg Law News (opens the article) ↗
AstraZeneca expands Karolinska obesity research partnership +5.02 headlines today · AstraZeneca is putting SEK 30 million towards obesity studies at Karolinska Institutet.
+5.0Research partnership broadened to cover obesity.lifesciencefocus.com (opens the article) ↗
+5.0Funding for obesity research at Swedish institute.The National Tribune (opens the article) ↗
AstraZeneca reduces its US sales workforce by 600 positions −3.02 headlines today · 21 in all, since 14 November · Reports say AstraZeneca is cutting 600 US commercial jobs as part of a savings plan.
−4.2Reported US job cuts.lifesciencefocus.com (opens the article) ↗
−3.3Sales staff reductions as part of cost savings drive.Medical Dialogues (opens the article) ↗
Ultomiris kidney result for AstraZeneca +7.91 headline today · 2 in all, since 13 November · The UAE conditionally approved Ultomiris for IgA nephropathy.
+7.5First conditional approval in UAE for kidney disease use.NAVLIN DAILY (opens the article) ↗
FDA declines Summit cancer drug AstraZeneca backed −6.71 headline today · Barron's reports the FDA did not yet approve a cancer drug from Summit, in which AstraZeneca had invested.
−6.7Regulator rejected partner's cancer drug after big investment.Barron's (opens the article) ↗
AstraZeneca reportedly eyeing $10bn deal +1.71 headline today · Investors' Chronicle discusses why AstraZeneca is considering a $10bn deal.
+1.7Possible large acquisition under consideration.Investors' Chronicle (opens the article) ↗
AstraZeneca Italy launches cancer narrative campaign +1.71 headline today · AstraZeneca Italy's head discussed a new cancer awareness narrative.
+1.7Local awareness campaign comments from Italian unit.jiji press (opens the article) ↗
AstraZeneca shares trade near resistance 0.01 headline today · A technical piece describes range-bound trading near a resistance level.
0.0Technical analysis showing sideways share trading.Traders Union (opens the article) ↗
AstraZeneca lobbying spend disclosed 0.01 headline today · A lobbying filing of $1.51 million was disclosed.
0.0Routine disclosure of lobbying spend.Quiver Quantitative (opens the article) ↗

Each article has its own score. The lines are our own summary; follow the source link to read the article itself.

Follow by email

A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.

How it works. Every morning an AI model reads the UK business news about each FTSE 100 company and scores how good or bad it is for the company, from −10 to +10. Pages update by about 07:45 UK time.

Not investment advice. MarketFrame rates the tone of news coverage. It is general information, not a recommendation to buy or sell anything. The scores are not share-price data or forecasts: a good score doesn't mean a share will rise, and a bad one doesn't mean it will fall.

Data to 06:30 UTC, 18 November · 867 headlines · 94 companiesMade by Adapt Progress Evolve Limited, a UK company · Privacy · Terms · Who we are · RSS · API · llms.txt